Lexicon Pharmaceuticals | LXRX - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
Abbott USD 10.4B 166M 2025-09
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 10.58M 5.55M 2025-12
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
AstraZeneca USD 19.05B 1.49B 2025-12
BioMarin Pharmaceutical USD 908.21M 117.95M 2025-12
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 19.46B 2.25B 2025-09
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Illumina USD 854M 125M 2025-12
Insmed USD 140.86M 75.6M 2025-12
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
J&J USD 17.61B 235M 2025-09
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
MacroGenics USD 13.37M 55.86M 2025-12
MannKind USD 38.37M 20.98M 2025-12
Merck USD 12.12B 596M 2025-09
Moderna USD 184M 862M 2025-12
Novartis USD 12.29B 3.3B 2025-12
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Thermo Fisher Scientific USD 8.9B 11M 2025-12
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
United Therapeutics USD 350.2M 52.5M 2025-12
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12